Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B

(2021) Nick S. Nurmohamed et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

(2020) Gregory G. Schwartz et al.   DIABETES CARE

HDL inhibits endoplasmic reticulum stress-induced apoptosis of pancreatic β-cells in vitro by activation of Smoothened

(2020) Mustafa Yalcinkaya et al.   JOURNAL OF LIPID RESEARCH

Lipids and Lipoproteins in 2020

(2020) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

What is ‘LDL cholesterol’?

(2019) Michael V. Holmes et al.   Nature Reviews Cardiology

Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events

(2019) Jane Armitage et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib

(2018) Donald M. Black et al.   CLINICAL PHARMACOKINETICS

Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk

(2018) W. Masson et al.   DIABETES & METABOLISM

Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults

(2018) Iona Y. Millwood et al.   JAMA Cardiology

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk

(2017) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease

(2017) Michael V. Holmes et al.   Nature Reviews Cardiology

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

(2017) A. Michael Lincoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Trials and Tribulations of CETP Inhibitors

(2017) Alan R. Tall et al.   CIRCULATION RESEARCH

Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes

(2016) Luca A. Lotta et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

(2016) John S. Millar et al.   JOURNAL OF CLINICAL INVESTIGATION

Statin-Associated Side Effects

(2016) Paul D. Thompson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes

(2016) Jon White et al.   JAMA Cardiology

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus

(2015) Joost Besseling et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches

(2015) David S. Small et al.   JOURNAL OF CLINICAL PHARMACOLOGY

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

(2015) Daniel I Swerdlow et al.   LANCET

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Apolipoprotein A-I Increases Insulin Secretion and Production From Pancreatic β-Cells via a G-Protein-cAMP-PKA-FoxO1–Dependent Mechanism

(2014) Blake J. Cochran et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

(2014) John Ford et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Loss-of-Function Mutations inABCA1and Enhanced β-Cell Secretory Capacity in Young Adults

(2014) Michael R. Rickels et al.   DIABETES

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

(2014) S. Kuhnast et al.   EUROPEAN HEART JOURNAL

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

(2013) Antonio M. Gotto et al.   AMERICAN JOURNAL OF CARDIOLOGY

Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective

(2013) Amir Hooshang Mohammadpour et al.   CLINICAL PHARMACOKINETICS

Evacetrapib at a Supratherapeutic Steady State Concentration Does Not Prolong QT in a Thorough QT/QTc Study in Healthy Participants

(2013) Jeffrey G. Suico et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Skeletal Muscle Insulin Resistance Associated with Cholesterol-Induced Activation of Macrophages Is Prevented by High Density Lipoprotein

(2013) Andrew L. Carey et al.   PLoS One

Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors

(2012) Shenping Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib

(2012) Michael Davidson et al.   JOURNAL OF LIPID RESEARCH

Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects

(2012) Trine Holm Johannsen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein

(2012) Lei Zhang et al.   Nature Chemical Biology

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

(2011) Philip J. Barter et al.   CIRCULATION

Torcetrapib impairs endothelial function in hypertension

(2011) Branko Simic et al.   EUROPEAN HEART JOURNAL

Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol

(2011) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

(2011) David Preiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

(2011) Guoqing Cao et al.   JOURNAL OF LIPID RESEARCH

Effects of High-Density Lipoproteins on Pancreatic β-Cell Insulin Secretion

(2010) Michelle A. Fryirs et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

HDL and LDL cholesterol significantly influence β-cell function in type 2 diabetes mellitus

(2010) Janine K Kruit et al.   CURRENT OPINION IN LIPIDOLOGY

Carriers of Loss-of-Function Mutations in ABCA1 Display Pancreatic  -Cell Dysfunction

(2010) M. Vergeer et al.   DIABETES CARE

Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes

(2010) Jukka Montonen et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus

(2009) Brian G. Drew et al.   CIRCULATION

Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction

(2009) Paul M. Ridker et al.   Circulation-Cardiovascular Genetics

Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries

(2009) Thomas A. Gaziano et al.   CURRENT PROBLEMS IN CARDIOLOGY

Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition

(2009) Xiao Hu et al.   ENDOCRINOLOGY

Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk

(2008) Alexander Thompson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE